两大跨国巨头称霸GLP-1市场,国产减肥药的机会在哪?

澎湃新闻
Yesterday

吃药减肥正在催生一个千亿级别的黄金赛道。高盛曾预估称,到2030年,全球抗肥胖症药物的市场规模可能会增长到约1000亿美元。在这条热门赛道,除了诺和诺德、礼来两大巨头你追我赶,另一边是包括更多中国药企也已跑步进场,展开竞速。  国内已经有仁会生物的贝那鲁肽和华东医药的利拉鲁肽两款GLP-1药物正式获批减重适应证。在研管线层面,2025年以来,翰森制药、联邦制药等国内药企的自研减肥药管线获得跨国药企...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10